Rossari Biotech Intrinsic Value
Rossari Biotech intrinsic value. Rossari Biotech (ROSSARI) median intrinsic value is ₹856.00 from 10 valuation models (range ₹128–₹1070), vs current price ₹428.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse Rossari Biotech annual reports for revenue, profit, balance sheet and cash flow data.
ROSSARI Valuation Methods Summary — DCF, Graham Number & P/E
Rossari Biotech intrinsic value across 10 models vs current price ₹428.00 — upside/downside and value range per method. Analyse Rossari Biotech ownership pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹336.96 | ₹269.57 - ₹404.35 | -21.3% | EPS: ₹28.08, Sector P/E: 12x |
| Book Value Method | asset | ₹1070.00 | ₹963.00 - ₹1177.00 | +150.0% | Book Value/Share: ₹1211.82, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹856.00 | ₹770.40 - ₹941.60 | +100.0% | Revenue/Share: ₹2541.82, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹856.00 | ₹770.40 - ₹941.60 | +100.0% | EBITDA: ₹352.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹802.65 | ₹642.12 - ₹963.18 | +87.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹179.71 | ₹161.74 - ₹197.68 | -58.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹231.38 | ₹208.24 - ₹254.52 | -45.9% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹856.00 | ₹770.40 - ₹941.60 | +100.0% | ROE: 11.7%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹875.00 | ₹787.50 - ₹962.50 | +104.4% | EPS: ₹28.08, BVPS: ₹1211.82 |
| Dividend Yield Method | dividend | ₹128.40 | ₹115.56 - ₹141.24 | -70.0% | DPS: ₹0.50, Target Yield: 3.5% |
ROSSARI Intrinsic Value vs Market Price — All Valuation Models
Rossari Biotech fair value range ₹128–₹1070 vs current market price ₹428.00 across 10 valuation models. For current market price and key ratios, visit Rossari Biotech stock price NSE.
ROSSARI Intrinsic Value Analysis — Undervalued or Overvalued?
Rossari Biotech median intrinsic value ₹856.00, current price ₹428.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of ROSSARI?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Rossari Biotech (ROSSARI) is ₹856.00 (median value). With the current market price of ₹428.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹128.40 to ₹1070.00, indicating ₹128.40 - ₹1070.00.
Is ROSSARI undervalued or overvalued?
Based on our multi-method analysis, Rossari Biotech (ROSSARI) appears to be trading below calculated value by approximately 100.0%.
ROSSARI Financial Health — Key Ratios vs Industry Benchmarks
Rossari Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 11.7% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 12.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.22x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ROSSARI Cash Flow Quality — Operating & Free Cash Flow
Rossari Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹65 Cr | ₹-45 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹137 Cr | ₹46 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹43 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹152 Cr | ₹62 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹29 Cr | ₹-121 Cr | Positive Operating Cash Flow | 6/10 |